AstraZeneca Pharma India Limited — Board Meeting, 14-08-2025: Outcome of Board Meeting

AstraZeneca Pharma India's board approved Q1 FY25-26 financial results, showcasing strong performance. Revenue from operations surged 36% year-on-year to ₹526.31 Cr. The company posted a significant profit after tax of ₹55.83 Cr, a turnaround from a loss last year. Growth was driven by diverse therapies, notably Oncology with ₹370.27 Cr in revenue. Strategically, the company secured four new approvals for expanded indications across its key medicines, reinforcing its leadership in Oncology and expanding its reach for patients with chronic and rare diseases.